Prevent cancer preclinical drug development program: preclinical efficacy and intermediate endpoint biomarkers-- targeting the parp pathway for the prevention of breast cancer
Active Awarded Last action
- Contract number
- 75N91022F00001
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,121,090
Award facts
- Opportunity
-
- TORFP2022E01 Solicitation number
- Contract value 100% obligated
- $1,121,090.00 Current and potential, with all options
- Completion date 88% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,121,090 |
About this award
The National Cancer Institute issued a $1.121 million delivery order to The University of Texas MD Anderson Cancer Center on June 1, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT) IDIQ for preclinical efficacy and biomarker evaluation targeting the PARP pathway for breast cancer prevention.
PREVENT is a $149.995 million multiple-award IDIQ contract active through January 24, 2029, supporting comprehensive evaluation of potential cancer preventive agents through preclinical efficacy testing and intermediate endpoint biomarkers. Place of performance is Houston, TX. The order is firm fixed-price with an ultimate completion date of May 31, 2027.
According to Service Contract Inventory reporting, MD Anderson invoiced $464 thousand in FY2023 and $278 thousand in FY2024, self-performing all reported hours with no subcontractor engagement.
Quick answers
Who was awarded contract 75N91022F00001?
75N91022F00001 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on June 1, 2022.
How much is contract 75N91022F00001 worth?
The government has obligated $1,121,090 on 75N91022F00001.
Is contract 75N91022F00001 an order under another contract?
Yes. 75N91022F00001 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91022F00001 competed?
The extent of competition for 75N91022F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award